TEAM - UDDHAV SHIGDEL

Uddhav Shigdel joined Hyku Biosciences in May of 2023. He has more than ten years of industry related early-stage drug discovery experience. Prior to joining the company, he was Director at Stablix and Principal Scientist at LifeMine Therapeutics contributing to the scientific foundation of these companies towards successful Series A funding. At Warp Drive Bio he played a major role in early discovery of KRAS inhibitors, which are the only compounds in clinical development that inhibit the active form of KRAS (G12C). He received his PhD in Chemistry and Chemical Biology from University of Chicago and completed a Postdoctoral Research Fellowship at Harvard University.